专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019136355A1 COMPOSITIONS AND METHODS FOR PAIN MANAGEMENT 审中-公开
公开(公告)号：WO2019136355A1
公开(公告)日：2019-07-11
申请号：PCT/US2019/012493
申请日：2019-01-07
申请人： LOMED INC.
发明人： BONNER, Dennis, James
IPC分类号： A61K31/485 , A61P25/04
CPC分类号： A61K31/485
摘要： Disclosed herein, in part, are pharmaceutical compositions comprising an opioid agonist such as codeine or a pharmaceutically acceptable salt thereof, hydroxyzine or a pharmaceutically acceptable salt thereof, a gabapentinoid, optionally a 5-HT3 antagonist and a pharmaceutically acceptable excipient. Methods of treating neuropathic and nociceptive pain comprising administering a disclosed pharmaceutical composition to a subject in need thereof is also provided herein.

2. 发明申请

WO2019126321A1 PHARMACEUTICAL COMPOSITION CONTAINING RESIN PARTICLES 审中-公开
公开(公告)号：WO2019126321A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066497
申请日：2018-12-19
申请人： DOW GLOBAL TECHNOLOGIES, LLC , ROHM AND HAAS COMPANY
发明人： TOCCE, Elizabeth , GEHRIS, Amie , SZEP, Silvia
IPC分类号： A61K9/14 , A61K31/485 , A61P25/04
CPC分类号： A61K9/146 , A61K31/485 , A61P25/04
摘要： Provided is a pharmaceutical composition comprising a collection of particles, wherein the particles comprise a drug and an ion exchange resin, wherein 90% or more by weight of the particles pass through a mesh screen having openings of 150μιτι, and wherein 90% or more by weight of the particles are retained on a mesh screen having openings of 106μιτι.

3. 发明申请

WO2019113470A1 NALOXONE TRANSDERMAL DELIVERY DEVICES AND METHODS FOR USING THE SAME 审中-公开
公开(公告)号：WO2019113470A1
公开(公告)日：2019-06-13
申请号：PCT/US2018/064513
申请日：2018-12-07
申请人： TEIKOKU PHARMA USA, INC.
发明人： HAYNES, Russell , WEN, Jianye , SHUDO, Jutaro , BERNER, Bret
IPC分类号： A61K9/70 , A61K31/485 , A61K47/32 , A61K47/12
CPC分类号： A61K9/7053 , A61K9/7061 , A61K31/485 , A61K47/12
摘要： Naloxone transdermal delivery devices are provided. Aspects of the naloxone transdermal delivery devices include a matrix comprising a naloxone active agent in a pressure sensitive adhesive and a backing layer. Also provided are methods of making and using the naloxone transdermal delivery devices, as well as kits containing the transdermal delivery devices. The devices, kits and methods of using the same find use in a variety of applications.

4. 发明申请

WO2019059376A1 ６－デオキシ－７，８－ジヒドロ－６－オキソモルヒネ骨格を有する化合物を薬効成分とする外用剤組成物审中-公开
公开(公告)号：WO2019059376A1
公开(公告)日：2019-03-28
申请号：PCT/JP2018/035190
申请日：2018-09-21
申请人：株式会社メドレックス
发明人：濱本　英利 , 辰巳　昇
IPC分类号： A61K31/485 , A61K9/70 , A61K47/12 , A61K47/18 , A61P25/04
CPC分类号： A61K9/70 , A61K31/485 , A61K47/12 , A61K47/18 , A61P25/04
摘要：本発明は、６－デオキシ－７，８－ジヒドロ－６－オキソモルヒネ骨格を有する化合物（例えば、ヒドロモルホン）、イオン液体、及び水を含有する、良好な経皮吸収性を示す外用剤組成物を提供する。

5. 发明申请

WO2019050974A1 ANALGESIC FORMULATION FOR CONTROL OF PAIN IN DOGS 审中-公开
公开(公告)号：WO2019050974A1
公开(公告)日：2019-03-14
申请号：PCT/US2018/049589
申请日：2018-09-05
申请人： KANSAS STATE UNIVERSITY RESEARCH FOUNDATION , LOCUSON, Charles W.
发明人： LOCUSON, Charles W. , KUKANICH, Stanley , KUKANICH, Katherine , RANKIN, David
IPC分类号： A61K31/135 , A61K31/4196 , A61P23/00
CPC分类号： A61P23/00 , A61K31/137 , A61K31/4196 , A61K31/445 , A61K31/4468 , A61K31/454 , A61K31/485 , A61K31/496 , A61K31/506 , A61K2300/00
摘要： Provided herein are treatments for reducing pain in dogs. The treatments generally comprise a combination of an opioid compound, such as methadone, and an azole compound, such as fluconazole. The treatments may further comprise an opioid abuse deterrent that advantageously inhibits opioid effects in humans while maintaining desirable analgesic effects in dogs. Additionally, the treatments provided herein avoid the undesirable side effects of prior art opioid treatments for dogs. The treatments may be administered as separate doses or in a single formulation product for improved compliance. The treatments have wide use potential in dogs from perioperative patients to inpatients and outpatients and may be used, for example, for sedation in minor procedures, analgesia, and decreasing temperature in canine patients.

6. 发明申请

WO2019026085A1 SUBLINGUAL FILM COMPOSITION 审中-公开
公开(公告)号：WO2019026085A1
公开(公告)日：2019-02-07
申请号：PCT/IN2018/050473
申请日：2018-07-20
申请人： ALKEM LABORATORIES LTD.
发明人： JAIN, Girish Kumar , DEWANGAN, Ashok , GAJULA, Koteswararao
IPC分类号： A61K9/00 , A61K47/10 , A61K31/485
CPC分类号： A61K9/006 , A61K31/485 , A61K2300/00
摘要： The present invention relates to a stable sublingual film comprising a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and a non-aqueous solvent, wherein the formulation does not use water and buffer, wherein the said buprenorphine and naloxone are solubilized during formation of the film, and wherein the film is stable for at least 6 months at 40ºC/75% RH condition.

7. 发明申请

WO2018208241A1 FORMULATION AND OPTIMIZATION OF CONTROLLED RELEASE TABLETS OF MORPHINE SULPHATE 审中-公开
公开(公告)号：WO2018208241A1
公开(公告)日：2018-11-15
申请号：PCT/TR2017/050178
申请日：2017-05-10
申请人： İLKO ILAÇ SANAYI VE TICARET ANONIM ŞIRKETI
发明人： ÖNCEL, Hatice , ÇAPAN, Yilmaz , PINARBAŞLI, Onur , ARSLAN, Aslihan , SARRAÇOĞLU, Nagehan
IPC分类号： A61K9/20 , A61K31/00
CPC分类号： A61K9/2013 , A61K9/2054 , A61K31/485
摘要： A stable solid controlled release formulation having a prolonged release of the active agent comprising morphine and/or one or several pharmaceutically acceptable salts thereof. The controlled release tablet is formulated with a controlled release matrix, wherein the matrix comprises a dual-action polymer mix consisting of a hydrophilic 0 polymer and a hydrophobic polymer.

8. 发明申请

WO2018183203A1 PACKAGED MULTI-DOSE LIQUID DRUG FORMULATION 审中-公开
公开(公告)号：WO2018183203A1
公开(公告)日：2018-10-04
申请号：PCT/US2018/024366
申请日：2018-03-26
申请人： DXM PHARMACEUTICAL, INC.
发明人： THUESEN, Mark, Lawrence , SANDERS, Steve, Shane , BANNISTER, Steve, J.
IPC分类号： A61K31/485 , A61K9/08 , A61K47/10 , A61P11/14
CPC分类号： A61P11/14 , A61J1/1406 , A61J1/1418 , A61J2205/30 , A61K9/0095 , A61K31/485 , A61K47/10 , A61K47/26
摘要： Multi-dose packaged over-the-counter antitussive syrups comprise a bottle containing about 75 ml or less of a liquid formulation of dextromethorphan hydrobromide. The liquid formulation provides at least two doses of dextromethorphan hydrobromide. Multi-dose packaged over-the-counter liquid formulations comprise a bottle having a capacity of about 100 ml or less, at least two doses of the liquid formulation carried within the bottle, a cap, a dosage cup releasably carried on the cap and a shrink wrap substantially enveloping the bottle and the dosage cup. Antitussive syrups comprise water, dextromethorphan hydrobromide in amounts from about 6 to about 25 mg/ml, and sweetener in amounts from about 200 to about 800 mg/ml.

9. 发明申请

WO2018024709A1 TAMPER RESISTANT DOSAGE FORM COMPRISING AN ANIONIC POLYSACCHARIDE 审中-公开
标题翻译：包含阴离子多糖的抗篡改剂型
公开(公告)号：WO2018024709A1
公开(公告)日：2018-02-08
申请号：PCT/EP2017/069393
申请日：2017-08-01
申请人： GRÜNENTHAL GMBH
发明人： WENING, Klaus , STOMBERG, Carmen
IPC分类号： A61K9/20 , A61K31/137
CPC分类号： A61K47/38 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K31/137 , A61K31/485 , A61K45/06 , A61K47/10
摘要： The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising -an opioid (A) selected from the group consisting of Oxymorphone, Oxycodone, Tapentadol, Hydromorphone, Hydrocodone, Morphine, and the physiologically acceptable salts thereof; wherein the weight content of the opioid (A) is within the range of from 5.0 to 35 wt.-%, based on the total weight of the pharmaceutical dosage form; -an anionic polysaccharide (B) selected from the group consisting of croscarmellose, carmellose, crosslinked carboxymethyl starch, carboxymethyl starch, and the physiologically acceptable salts thereof; wherein the weight content of the anionic polysaccharide (B) is within the range of from 5.0 to 35 wt.-%, based on the total weight of the pharmaceutical dosage form; and -a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol; wherein the weight content of the polyalkylene oxide (C) is within the range of from 20 to 80 wt.-%, based on the total weight of the pharmaceutical dosage form; wherein the opioid (A) is present in a controlled-release matrix comprising the anionic polysaccharide (B) and the polyalkylene oxide (C).
摘要翻译：本发明涉及断裂强度至少为300N的药物剂型，所述剂型包含选自羟吗啡酮，羟考酮，他喷他多，氢吗啡酮，氢可酮，吗啡及其生理上可接受的盐; 其中所述阿片样物质（A）的重量含量基于所述药物剂型的总重量在5.0至35重量％的范围内; - 选自交联羧甲基纤维素，羧甲基纤维素，交联羧甲基淀粉，羧甲基淀粉及其生理上可接受的盐的阴离子多糖（B）其中基于所述药物剂型的总重量，所述阴离子多糖（B）的重量含量在5.0至35重量％的范围内; 和 - 重均分子量为至少200,000g / mol的聚环氧烷（C）其中所述聚环氧烷（C）的重量含量基于所述药物剂型的总重量在20至80重量％的范围内; 其中阿片样物质（A）存在于包含阴离子多糖（B）和聚环氧烷（C）的控释基质中。

10. 发明申请

WO2017147285A1 SUSTAINED RELEASE BUPRENORPHINE MICROSPHERES (SRBM) AND METHODS OF USE THEREOF 审中-公开
标题翻译：持续释放丁丙诺啡微球（SRBM）及其使用方法
公开(公告)号：WO2017147285A1
公开(公告)日：2017-08-31
申请号：PCT/US2017/019110
申请日：2017-02-23
申请人： BIODELIVERY SCIENCES INTERNATIONAL, INC.
发明人： VASISHT, Niraj , FINN, Andrew
IPC分类号： A61K9/00 , A61K47/34 , A61K9/16 , A61K31/485 , A61P25/04 , A61P25/36
CPC分类号： A61K31/485 , A61K9/0019 , A61K9/1617 , A61K9/1635 , A61K9/1647
摘要： The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.
摘要翻译：本发明涉及能够递送丁丙诺啡，其代谢物或其前药约7天至约6个月的持续释放的丁丙诺啡微球（SRBM）制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式